 CAMBRIDGE, England BOSTON--BUSINESS WIRE--Bicycle Therapeutics plc NASDAQ:BCYC, a clinical-stage biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide Bicycle technology, today announced that it has entered into a settlement and license agreement with Pepscan Systems B.V. regarding Bicycles use of Pepscans CLIPS peptide technology. The companies have agreed to settle all intellectual property disputes worldwide. Unde 